Medications for preventing hypertensive disorders in high-risk pregnant women: a systematic review and network meta-analysis
- PMID: 35778751
- PMCID: PMC9250249
- DOI: 10.1186/s13643-022-01978-5
Medications for preventing hypertensive disorders in high-risk pregnant women: a systematic review and network meta-analysis
Abstract
Objectives: To determine the relative effectiveness of medications for preventing hypertensive disorders in high-risk pregnant women and to provide a ranking of medications using network meta-analysis.
Methods: All randomized controlled trials comparing the most commonly used medications to prevent hypertensive disorders in high-risk pregnant women that are nulliparity and pregnant women having family history of preeclampsia, history of pregnancy-induced hypertension in previous pregnancy, obstetric risks, or underlying medical diseases. We received the search results from the Cochrane Pregnancy and Childbirth's Specialised Register of Controlled Trials, searched on 31st July 2020. At least two review authors independently selected the included studies and extracted the data and the methodological quality. The comparative risk ratios (RR) and 95% confidence intervals (CI) were analyzed using pairwise and network meta-analyses, and treatment rankings were estimated by the surface under the cumulative ranking curve for preventing preeclampsia (PE), gestational hypertension (GHT), and superimposed preeclampsia (SPE). Safety of the medications is also important for decision-making along with effectiveness which will be reported in a separate review.
Results: This network meta-analysis included 83 randomized studies, involving 93,864 women across global regions. Three medications, either alone or in combination, probably prevented PE in high-risk pregnant women when compared with a placebo or no treatment from network analysis: antiplatelet agents with calcium (RR 0.19, 95% CI 0.04 to 0.86; 1 study; low-quality evidence), calcium (RR 0.61, 95% CI 0.47 to 0.80; 13 studies; moderate-quality evidence), antiplatelet agents (RR 0.69, 95% CI 0.57 to 0.82; 31 studies; moderate-quality evidence), and antioxidants (RR 0.77, 95% CI 0.63 to 0.93; 25 studies; moderate-quality evidence). Calcium probably prevented PE (RR 0.63, 95% CI 0.46 to 0.86; 11 studies; moderate-quality evidence) and GHT (RR 0.89, 95% CI 0.84 to 0.95; 8 studies; high-quality evidence) in nulliparous/primigravida women. Few included studies for the outcome of superimposed preeclampsia were found.
Conclusion: Antiplatelet agents, calcium, and their combinations were most effective medications for preventing hypertensive disorders in high-risk pregnant women when compared with a placebo or no treatment. Any high-risk characteristics for women are important in deciding the best medications. The qualities of evidence were mostly rated to be moderate.
Systematic review registration: PROSPERO CRD42018096276.
Keywords: High-risk pregnant women; Hypertension prevention; Hypertensive disorders in pregnancy; Medications; Network meta-analysis.
© 2022. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Maternal-neonatal events resulting from medications for preventing hypertensive disorders in high-risk pregnant women: A systematic review and network meta-analysis.Int J Gynaecol Obstet. 2024 Jan;164(1):19-32. doi: 10.1002/ijgo.14910. Epub 2023 Jun 18. Int J Gynaecol Obstet. 2024. PMID: 37332168 Review.
-
Antiplatelet agents for preventing pre-eclampsia and its complications.Cochrane Database Syst Rev. 2019 Oct 30;2019(10):CD004659. doi: 10.1002/14651858.CD004659.pub3. Cochrane Database Syst Rev. 2019. PMID: 31684684 Free PMC article.
-
Calcium supplementation commencing before or early in pregnancy, or food fortification with calcium, for preventing hypertensive disorders of pregnancy.Cochrane Database Syst Rev. 2017 Sep 26;9(9):CD011192. doi: 10.1002/14651858.CD011192.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2019 Sep 16;9:CD011192. doi: 10.1002/14651858.CD011192.pub3. PMID: 28949421 Free PMC article. Updated. Review.
-
Calcium supplementation commencing before or early in pregnancy, for preventing hypertensive disorders of pregnancy.Cochrane Database Syst Rev. 2019 Sep 16;9(9):CD011192. doi: 10.1002/14651858.CD011192.pub3. Cochrane Database Syst Rev. 2019. PMID: 31523806 Free PMC article.
-
Uterotonic drugs to prevent postpartum haemorrhage: a network meta-analysis.Health Technol Assess. 2019 Feb;23(9):1-356. doi: 10.3310/hta23090. Health Technol Assess. 2019. PMID: 30821683 Free PMC article.
Cited by
-
Effects of aerobic, strength, and combined training during pregnancy in the blood pressure: A systematic review and meta-analysis.Front Physiol. 2022 Aug 30;13:916724. doi: 10.3389/fphys.2022.916724. eCollection 2022. Front Physiol. 2022. PMID: 36111150 Free PMC article.
-
Results of a Five-Year Experience in First Trimester Preeclampsia Screening.J Clin Med. 2022 Aug 4;11(15):4555. doi: 10.3390/jcm11154555. J Clin Med. 2022. PMID: 35956169 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical